US 6472431

I'll search for authoritative information on this patent number and check for any CAFC 2026 docket activity.

Let me refine my search for CAFC 2026 activity and confirm procedural history.

Let me retrieve the actual claim set of the '431 patent to describe the independent claims accurately.

US Patent 6,472,431 — Analyst Summary

Scope note: I searched USPTO materials and Federal Circuit docket sources as instructed. I found no CAFC 2026 docket or appeal activity involving US 6,472,431. The Federal Circuit activity I did find in this technology area (Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals, Nos. 24-2274/-2277/-2278, decided May 6, 2025) concerns different patents (e.g., U.S. 11,147,782), not the '431 patent. Accordingly, I cannot report any 2026 appellate docket for this patent, and I flag that as a factual gap rather than a null result I can positively verify in real time.

Bibliographic data

Abstract (as published)

"Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient."

Independent claim — plain-language overview

The '431 patent has one independent claim (claim 1); claims 2–7 all depend from it. All seven claims are method claims (not composition claims). Confirmed claim 1 text:

"1. A method of rendering an aqueous medium resistant to microbial growth, comprising adding the gamma-hydroxybutyrate salt to the aqueous medium, adjusting the concentration of the gamma-hydroxybutyrate salt in the aqueous medium to a final concentration of at least about 250 mg/ml, and adjusting the pH of the medium to a final pH of about 6 to about 10, so that the medium is chemically stable and resistant to microbial growth."

Plain language: To practice claim 1, you take an aqueous (water-based) liquid, add a GHB salt to it, bring the GHB concentration up to at least ~250 mg/mL, and set the pH between roughly 6 and 10. The claimed result is a solution that both resists microbial growth and is chemically stable — i.e., the high GHB concentration itself acts as a self-preserving agent, without necessarily needing a preservative.

Dependent claims (2–7), summarized:

• 2 — the salt is sodium gamma-hydroxybutyrate (sodium oxybate).
• 3 — concentration about 310–750 mg/mL and pH about 6–9.
• 4 — the medium contains no preservative.
• 5 — concentration about 250–750 mg/ml.
• 6 — the pH-adjusting agent is an organic acid.
• 7 — the acid is selected from malic, citric, acetic, boric, lactic, hydrochloric, phosphoric, sulfuric, sulfonic, and nitric acid.

(Note the drafting quirk: claims 6–7 refer to "said pH-adjusting agent," although claim 1 does not expressly recite a pH-adjusting agent. This mismatch was flagged in later litigation as a possible §112 basis — see below.)

Prosecution / family context

• Claim 1 corresponds to application claim 70, which was amended during prosecution to add "adding the gamma-hydroxybutyrate salt to the aqueous medium"; the examiner allowed it after applicant argued that the prior art (US 4,983,632 and/or US 5,840,331) did not teach using a GHB salt at ≥250 mg/mL as a microbial-growth-resistant agent.
• The '431 patent is the parent of a large divisional/continuation family covering the XYREM® franchise, including US 6,780,889; 7,262,219; 7,851,506; 8,263,650; 8,461,203; 8,324,275; 8,859,619; and 8,952,062.
• Litigation history (per Google Patents and court records): Numerous consolidated New Jersey District Court suits (e.g., 2:13-cv-00391 Jazz v. Amneal, plus additional 2011–2017 NJ cases), and PTAB case IPR2016-00370 (terminated by settlement). In the NJ actions, defendants (Amneal, Par, Lupin, Watson) challenged the '431 claims under §§102/103 and §112 (written description, enablement, indefiniteness, and improper multiple-dependent claims 4 and 7).

Stated uncertainty

1. No CAFC 2026 docket for 6,472,431 was found. Given the patent's 2019 expiry, 2026 appellate activity is unlikely, but I cannot positively confirm the absence of a dormant or sealed appeal from the sources retrieved.
2. The current assignee shown by Google Patents (Jazz Pharmaceuticals Inc / JPI Commercial LLC) is explicitly labeled by that source as possibly inaccurate; I did not independently verify the chain of title through USPTO Assignment records.
3. I did not independently retrieve the full issued claim set from the USPTO full-text database; claim 1 and dependents are corroborated by the patent's prosecution papers (application claims 70–76) and the Radaris "What is claimed" excerpt, which agree. If a verbatim issued-claims verification is needed, the USPTO PatentCenter full text should be consulted directly.

I'll research litigation involving US patent 6472431 (the "Jazz Pharmaceuticals / Orphan Medical" sodium oxybate patent). Let me run several targeted searches.

I have good leads. Let me dig deeper into the specific case numbers listed on the patent page and identify defendants and outcomes.

Let me pin down the remaining case numbers and their defendants/outcomes.

I've reached my tool-call limit, so I'll compile the findings from the searches I completed. Below is what the record shows for U.S. Patent No. 6,472,431 ("the '431 patent") — "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy" (issued Oct. 29, 2002; originally Orphan Medical, Inc.; now Jazz Pharmaceuticals). Please note the caveats at the end.

Context

The '431 patent is the parent of the "'431 patent family" covering sodium oxybate (Xyrem®) formulations. It was asserted in the Hatch-Waxman/ANDA litigation campaign Jazz Pharmaceuticals waged across the 2010s against every generic applicant seeking to market sodium oxybate. Almost all of these cases involved the '431 patent together with other members of the family (U.S. 6,780,889; 7,262,219; 7,851,506; 8,263,650; 8,324,275; 8,461,203), so the '431 patent was typically one of several patents-in-suit rather than the sole patent.

Litigation specifically involving the '431 patent

The Google Patents "family litigation" record for US6472431B2 lists the following actions (docket numbers taken verbatim from that record):

Important caveats

1. Not all '431 cases were standalone. The Roxane matters were consolidated into a single case (Civil Action No. 10-6108), and the Amneal/Par/NJ matters were consolidated (2:13-cv-00391). Docket numbers 2:10-cv-06108, 2:11-cv-00660, 2:12-cv-06761, 2:12-cv-07459, 2:13-cv-00391, 2:13-cv-05450 and 2:13-cv-07884 all directly concern the '431 patent family.

2. Defendants I could NOT confirm for case numbers 2:15-cv-05619, 2:15-cv-06548, 2:17-cv-05487 and 2:17-cv-04439. Based on the timeline of Paragraph IV filings (Wockhardt June 8, 2015; Lupin July 23, 2015), the two 2015 NJ cases most likely name Wockhardt and/or Lupin, but I did not verify this, so I flag it as unconfirmed rather than assert it. I also ran out of search steps before confirming the E.D.N.Y. (2:17-cv-04439) defendant.

3. The Avadel litigation is NOT about the '431 patent. The high-profile Jazz v. Avadel (Lumryz/FT218) case and the Fed. Cir. Orange-Book delisting decision (Feb. 24, 2023) concern U.S. 8,731,963 and other "distribution-system" patents, not the '431 patent. I excluded them.

4. The '431 patent's role in antitrust litigation is derivative. The settlements above are the subject of the In re Xyrem (Sodium Oxybate) Antitrust Litigation, N.D. Cal. (3:20-md-02966), with related complaints in D. Minn. (1:21-cv-00737), M.D. Fla. (3:20-cv-04667) and elsewhere (e.g., 3:23-cv-01453). In those suits the 2010–2018 '431-patent ANDA settlements are pleaded as the predicate for the alleged reverse-payment scheme — so the '431 patent appears as background, not as a patent asserted in those antitrust cases.

5. Outcome summary: All of the '431-patent infringement actions that I could confirm were resolved by settlement/license, not by a final judgment of infringement or invalidity. The single PTAB proceeding tied to the '431 patent family (IPR2016-00370) also terminated by settlement. The '431 patent itself expired December 22, 2019 (Google Patents: "Anticipated expiration; Expired – Lifetime").

6. Sources: Google Patents family-litigation record for US6472431B2 (portal.unifiedpatents.com and darts-ip links), the D.N.J. Markman Opinion in Jazz Pharms. v. Roxane (2:10-cv-06108, D.E. 151, Sept. 14, 2012), the Amneal Complaint (Jan. 18, 2013), SEC Form 8-K disclosures by Jazz Pharmaceuticals (Jan. 18, 2013) and Endo International (Dec. 27, 2013), and the Xyrem antitrust complaints (2020). Because my searches hit a step limit, I recommend verifying the four unconfirmed docket numbers directly on PACER or the Unified Patents litigation portal (portal.unifiedpatents.com/litigation) before relying on them.

I'll start by checking the canonical PTAB block against what the patent page itself shows, then fill in details via web search.

Found IPR2016-00370. Let me verify whether other IPRs (e.g., from the Wockhardt batch or Amneal/Par) also targeted the '431 patent.

Let me get the petition grounds for IPR2016-00370 and check for any other IPR targeting the '431 patent.

Proceedings overview

One AIA trial proceeding on file — and it never reached the merits. The USPTO Open Data Portal block supplied in this prompt returns zero AIA proceedings for US 6,472,431, but the patent's own Google Patents family/litigation record lists IPR2016-00370 (Settlement), and third-party PTAB dockets confirm it: Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc., filed 2015-12-22, terminated 2016-05-17 on a joint motion for settlement before any institution decision was ever rendered. Breakdown: 0 active · 0 claims invalidated · 0 claims sustained · 1 settled (pre-institution) · 0 institution denials on the merits. The bottom-line defensive posture: the patent is not "hardened" — it is simply un-adjudicated. No claim of US 6,472,431 has ever been tested by the PTAB, no final written decision exists, and no § 315(e)(2) estoppel attaches to anyone. Combined with the fact that the '431 patent expired 2019-12-22, the practical posture for a defendant today is not "the troll has no case" but "the patent is time-barred from meaningful damages and its validity is entirely untested."

⚠️ Data-integrity flag: the ODP "PTAB proceedings on file" block is incomplete here. IPR2016-00370 is a PRPS-era proceeding (2015–2016) and does not appear in the ODP AIA-trial index, but it demonstrably exists — it appears on the patent's own Google Patents family litigation record and on Docket Alarm and GreyB/PTAB-verse. Treat the ODP zero as an indexing gap, not as evidence that the patent was never challenged.

IPR2016-00370 — Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review (35 U.S.C. §§ 311–319)
• Filed: 2015-12-22
• Status: "PTAB case IPR2016-00370 filed (Settlement)" (verbatim, Google Patents family record). Some third-party databases label this "Institution Denied" with an "institution decision date" of 2016-05-17 — that label is wrong and the date is misleading. Paper 14 entered 2016-05-17 is captioned Order Termination of the Proceedings under 37 C.F.R. §§ 42.72, 42.74; it is a settlement termination, not a merits denial. No institution decision on the petition was ever entered.
• Judge panel: Jacqueline Wright Bonilla, Sheridan K. Snedden, and Susan L. C. Mitchell, Administrative Patent Judges (per the face of the 2016-05-17 termination order; the third name is truncated in the indexed copy).
• Petition grounds: Not established. Because the case terminated pre-institution with no FWD and no public institution decision, the grounds (claims challenged, references, § 102 / § 103 / § 112 basis) were never adjudicated and are not disclosed in the sources I could access. I will not guess at them. What is knowable: Wockhardt's parallel 2015 petitions against Jazz's other Xyrem patents (IPR2015-00545, -00546, -00547, -00548, -00551, -00554, -01813, -01814, -01815, -01816, -01818, -01820) attacked the restricted-distribution-system family under § 103 — a different family and a different subject matter from the '431 formulation patent. Do not impute those grounds to IPR2016-00370.
• Institution decision: None issued. The Board's 2016-04-19 email authorization (Jazz Ex. 2002) permitted the parties to file a joint motion to terminate under 37 C.F.R. § 42.72 and to seal the settlement agreement.
• Final Written Decision: None. No claim of the '431 patent was canceled, confirmed, or otherwise adjudicated in this proceeding.
• Settlement / termination: On 2016-04-20 the parties filed a Joint Motion to Terminate (Paper 12) and a Joint Request to Treat the Settlement Agreement as Business Confidential Information (Paper 13), citing 35 U.S.C. § 317(a)–(b). The Board granted both on 2016-05-17, terminated the proceeding, and ordered that the filed settlement agreement (Ex. 2003) be kept as business confidential information under § 317(b) and 37 C.F.R. § 42.74(c) as "Parties and Board Only" in PRPS. The terms are confidential — the Board expressly found the agreement "contains confidential business information regarding the terms of settlement." A Notice of Refund (Paper 16, 2016-06-03) refunded $14,000 in post-institution fees to Petitioner. The Board noted the parties represented that related district court proceedings "remain pending against other defendants" and that a stipulation and order of dismissal had been filed in the related district court.
• Appeal: None. With no FWD, there was no appealable decision; no Federal Circuit docket exists for this proceeding.
• Defensive value: A defendant today gets nothing usable from this proceeding — no cancellation, no estoppel, no construction, no prior-art finding. Its only tactical use is the negative inference that Jazz bought peace with Wockhardt portfolio-wide in April–May 2016, and that the '431 patent's validity was never litigated to judgment at the PTAB.

Key documents (Docket Alarm's public mirror of the PTAB file):

• Termination order, 2016-05-17: https://www.docketalarm.com/cases/PTAB/IPR2016-00370/Inter_Partes_Review_of_U.S._Pat._6472431/docs/05-17-2016-Board/Termination-14-Order_Termination_of_the_Proceedings.pdf
• Notice of refund, 2016-06-03: https://www.docketalarm.com/cases/PTAB/IPR2016-00370/Inter_Partes_Review_of_U.S._Pat._6472431/06-03-2016-Board/Notice-16-Notice_of_Refund/
• Case profile: https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2016-00370

Strategic summary

Claim status: everything is UNTESTED. No claim of US 6,472,431 has been canceled; no claim has been sustained; there is no narrowing amendment, no certificate, and no FWD. The only AIA proceeding ever filed against this patent settled out before institution, so the entire claim set remains exactly as issued in 2002 — but with zero PTAB validity adjudication behind it. Note also that because no FWD ever issued in IPR2016-00370, nothing in the file establishes which claims were even challenged, and I will not infer a claim list from Wockhardt's other petitions.

Estoppel: none, in either direction. Section 315(e)(2) estoppel arises only for a petitioner that obtained a final written decision. IPR2016-00370 terminated under § 317(a) before institution, so Wockhardt Bio AG is not estopped, and no other party is estopped by anything in this file. For a defendant currently being asserted against, that cuts both ways: every prior-art ground remains fully available to you in district court and in a fresh IPR (subject to your own § 315(b) one-year bar running from service of the complaint), and you are not locked out of art that Wockhardt raised or reasonably could have raised. Conversely, you get no free ride from an earlier petitioner's work product — you must build the invalidity case yourself.

Pattern signals. Wockhardt was a serial challenger of Jazz's Xyrem portfolio in 2015: it filed or joined in at least a dozen IPRs across the distribution-system family (IPR2015-00545/546/547/548/551/554 joinders, and IPR2015-01813/814/815/816/818/820), with IPR2016-00370 as its lone shot at the '431 formulation patent. Jazz's counter-strategy was blanket settlement: in April 2016 it requested authorization to terminate all of those proceedings via a single confidential agreement with Wockhardt, and it simultaneously dismissed Wockhardt from the related district court actions. That is the pattern that killed IPR2016-00370 — Jazz traded an administrative win to remove a generic from the litigation, not a merits defense of the claims. No defensive aggregator was the petitioner here. The "Unified Patents" attribution on the Google Patents page refers to Unified's PTAB data licensing ("Unified Patents PTAB Data," CC-BY 4.0), not to Unified Patents as petitioner — do not read a coordinated RPX/Unified-style attack into this file. Separately, Jazz has litigated hard where it lost: it appealed the adverse '730-family FWDs and lost in Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. 2018) — but none of that involved the '431 patent.

The expiration point dominates everything. Per Jazz's own litigation filings and the Google Patents record, the '431 patent expired 2019-12-22 (its original application US 09/470,570 was filed 1999-12-22, so the term has fully run). A defendant accused today faces a § 286 six-year damages lookback reaching only to 2020-10-01 — after the patent's expiration. There is no meaningful past-damages window left. If a demand letter or complaint cites the '431 patent in 2026, the jurisdictional and remedies flaws are as important as invalidity.

Recommended next steps

1. If you are a defendant and the letter cites the '431 patent specifically: the strongest response is not an IPR — it is expiration plus the § 286 damages bar. Quote the file: the '431 patent's term ran from a 1999-12-22 filing and expired 2019-12-22. Six years back from today is 2020-10-01, which falls entirely after expiration. There is no compensable infringement window. Escalate with a Rule 11 / § 285 letter rather than briefing validity.
2. If you still need validity cover (e.g., for a declaratory-judgment posture or as a hedge): because no FWD issued in IPR2016-00370, no § 315(e)(2) estoppel applies to you, and all § 102/§ 103/§ 112 grounds are open. But weigh cost against the patent's expired status — an IPR against an expired patent that cannot generate damages is rarely a rational spend, and the Board is unlikely to institute on a patent with no live assertion (and, where the patent has expired, institution is discretionary at best).
3. Do not rely on the ODP block as proof of "no PTAB history." The ODP index here is demonstrably missing IPR2016-00370. Before you represent to a court or a client that "no AIA proceeding has ever been filed against the '431 patent," pull the PRPS-era file directly: PTAB E2E / PTAB Center at https://ptab.uspto.gov and the litigation/assignment records at https://patents.google.com/patent/US6472431/en, plus https://www.docketalarm.com/cases/PTAB/IPR2016-00370/ for the papers. I could not retrieve the underlying 2015-12-22 petition in the public sources available to me, so the precise challenged claims and grounds remain unverified — do not state a claim list or reference list for IPR2016-00370 without pulling Paper 2 from the file.
4. Check the '431 family separately. Jazz asserted a cluster of patents said to cover the same chemically stable, microbially resistant GHB formulation — the '431 family ('889, '219, '506, '650, '275, '062 and others). Those are different patents with different, and here untested, PTAB histories; the '730-family invalidations (Jazz v. Amneal, 895 F.3d 1347) concern the restricted-distribution patents, not this formulation family. Do not conflate them when assessing what a demand letter actually puts at risk.

Confidence note: the existence, date, petitioner, panel, and settlement termination of IPR2016-00370 are well-supported by multiple independent sources (Board order text, Docket Alarm, GreyB). The petition's grounds and the number of challengers styled as "et al." are not verified and are expressly flagged as unknown above.

I'll research this patent's ownership chain from available sources before writing. Let me run several searches in parallel.

Let me try to locate reel/frame specifics and confirm the 2005 acquisition vehicle.

US 6,472,431 — Ownership & Assignment Reconstruction

Scope note / source limitation (read first). The USPTO Patent Assignment Search records were not retrievable with the tools available to me for this run. The Google Patents legal-events mirror for US6472431 does expose the recorded conveyance types, assignors and assignees, and event dates, but it does not expose reel/frame numbers or the correspondent of record. I have therefore built the chain below from the Google Patents reassignment record (https://patents.google.com/patent/US6472431/en) and corroborated each step against SEC filings, merger agreements, and litigation documents. Reel/frame and correspondent fields are marked NOT RETRIEVED rather than guessed. Anyone relying on this for standing or ownership analysis must re-pull the reel/frame and correspondent data at https://assignmentcenter.uspto.gov/ (patent number search: 6472431) — I flag below exactly where correspondent data would be dispositive and is currently missing.

Inventors

All five inventors were Orphan Medical employees; the invention arose out of Orphan's Xyrem (sodium oxybate) development program. The 1999-12-22 application (Ser. No. 09/470,570) claims priority to provisional 60/113,745 filed 1998-12-23.

Unusual patterns: none detected. There is no evidence of inventor departure within 12 months of filing, and no evidence of an inventor-held or inventor-assigned residual interest surviving the 2000-08-17 assignment to Orphan. The inventor roster was stable and the patent stayed inside the Orphan → Jazz corporate line throughout. One note worth flagging for prosecution-history purposes (not an NPE signal): litigation opponents alleged that the later patents in the '431 family were drafted by "patent-counsel-invented" claims without inventor involvement (Roxane counterclaims, D.N.J. 2:15-cv-01360). That is an inequitable-conduct allegation, not an ownership irregularity.

Original assignee

Orphan Medical, Inc. — named on the face of the issued patent. Incorporated 1994 in Minnesota, reincorporated in Delaware 2000-09-01, principal offices at 13911 Ridgedale Drive, Suite 250, Minnetonka, MN 55305.

• Primary business: specialty pharma developing products for rare diseases. Orphan did ship a product embodying the claims: it obtained FDA approval of Xyrem (sodium oxybate) oral solution, NDA No. 21-196, on 2002-07-17, for cataplexy associated with narcolepsy, and commercially launched it. Xyrem was the first approved treatment for that indication.
• Current status: no longer independent. Acquired by Jazz Pharmaceuticals, Inc. via reverse merger on 2005-07-29 (Agreement and Plan of Merger dated 2005-04-18 among Jazz Pharmaceuticals, Inc. as Buyer, Twist Merger Sub, Inc. as Sub, and Orphan Medical, Inc., at ~$10.75/share, ≈$122.6M). Orphan survived as a Jazz subsidiary and later became Orphan Medical, LLC. Orphan Medical also pled guilty to felony misbranding in 2007 and paid ~$20M in the DOJ settlement — a regulatory event, not an insolvency event.

Assignment timeline

All dates below are as reported in the Google Patents legal-events reassignment record for US6472431. That source does not distinguish execution date from recording date, so each entry shows the single reported date and must be verified against the Assignment Center record. Reel/frame and correspondent: NOT RETRIEVED for every entry. The 2010-11-12 / 2010-11-26 duplication is flagged explicitly as an unresolved anomaly.

2000-08-17 — Reel NOT RETRIEVED

• Conveyance: Assignment of assignors' interest
• Assignor: Cook, Harry; Hamilton, Martha; Danielson, Douglas; Goderstad, Colette; Reardan, Dayton (five named inventors)
• Assignee: Orphan Medical, Inc.
• Correspondent: NOT RETRIEVED
• Context: Standard employee/employer title confirmation — inventors assign their rights to the operating company that filed the application. Routine; not an NPE event.

2000-08-25 — Reel NOT RETRIEVED

• Conveyance: Assignment of assignors' interest
• Assignor: Orphan Medical, Inc. (a Minnesota corporation)
• Assignee: Orphan Medical, Inc., a Delaware corporation
• Correspondent: NOT RETRIEVED
• Context: Internal corporate reincorporation (Minnesota → Delaware, effective 2000-09-01 per the Orphan Medical proxy statement). Pure housekeeping; no change in beneficial owner.

2005-07-29 — Reel NOT RETRIEVED

• Conveyance: Security interest
• Assignor: Twist Merger Sub, Inc.
• Assignee: LB 1 Group Inc.
• Correspondent: NOT RETRIEVED
• Context: Securitization / acquisition financing — collateral grant securing the $80,000,000 15% Senior Secured Notes due 2011 issued by Twist Merger Sub, Inc. (Jazz's wholly owned merger subsidiary) to fund the Orphan Medical acquisition. This is a lien, not a transfer of title. Cross-referenced to the Senior Secured Note and Warrant Purchase Agreement dated 2005-06-24 (Jazz 10-K exhibit index).

2008-04-04 — Reel NOT RETRIEVED

• Conveyance: Security agreement
• Assignor: JPI Commercial, LLC
• Assignee: LB I Group Inc.
• Correspondent: NOT RETRIEVED
• Context: Continuation/re-grant of the securitization lien, now recorded against the Jazz IP-holding subsidiary JPI Commercial, LLC rather than the merger vehicle. Financing collateral, not an ownership transfer.

2010-06-30 — Reel NOT RETRIEVED

• Conveyance: Release by secured party
• Assignor: LB I Group Inc.
• Assignee: JPI Commercial, LLC
• Correspondent: NOT RETRIEVED
• Context: Lien release on payoff/refinancing of the 2005 note facility. Not a title transfer.

2010-06-30 — Reel NOT RETRIEVED

• Conveyance: Security agreement
• Assignor: JPI Commercial, LLC
• Assignee: Silicon Valley Bank
• Correspondent: NOT RETRIEVED
• Context: New secured lender substituted for LB I Group under the same-day refinancing (SVB release letter and UCC-3 termination appear in the same 2005 financing exhibit set). Securitization, not ownership.

2010-11-12 — Reel NOT RETRIEVED

• Conveyance: Merger
• Assignor: Orphan Medical, Inc.
• Assignee: Orphan Medical, LLC
• Correspondent: NOT RETRIEVED
• Context: Internal reorganization — Orphan Medical, Inc. converted/merged into Orphan Medical, LLC inside the Jazz group. Title vesting by operation of law.

2010-11-12 — Reel NOT RETRIEVED

• Conveyance: Assignment of assignors' interest
• Assignor: Orphan Medical, LLC
• Assignee: JPI Commercial, LLC
• Correspondent: NOT RETRIEVED
• Context: Internal IP consolidation into Jazz's commercial/holding subsidiary. Not a third-party sale.

2010-11-17 — Reel NOT RETRIEVED

• Conveyance: Assignment of assignors' interest
• Assignor: JPI Commercial, LLC
• Assignee: Jazz Pharmaceuticals, Inc.
• Correspondent: NOT RETRIEVED
• Context: Internal reorganization — record title brought up to the ultimate parent operating company ahead of the Xyrem ANDA litigation wave.

2010-11-26 — Reel NOT RETRIEVED

• Conveyance: Merger
• Assignor: Orphan Medical, Inc.
• Assignee: Orphan Medical, LLC
• Correspondent: NOT RETRIEVED
• Context: Duplicate/corrective recording of the 2010-11-12 merger entry. Appears twice in the legal-events record with the same parties. I cannot resolve whether this is a corrective re-record or a second, distinct subsidiary transaction without the reel/frame numbers — flagging, not resolving.

2010-11-26 — Reel NOT RETRIEVED

• Conveyance: Assignment of assignors' interest
• Assignor: Orphan Medical, LLC
• Assignee: JPI Commercial, LLC
• Correspondent: NOT RETRIEVED
• Context: Duplicate/corrective recording of the 2010-11-12 assignment entry. Same caveat as above.

2010-12-22 — Reel NOT RETRIEVED

• Conveyance: Assignment of assignors' interest
• Assignor: JPI Commercial, LLC
• Assignee: Jazz Pharmaceuticals, Inc.
• Correspondent: NOT RETRIEVED
• Context: Second pass of the internal reorganization recording (repeats the 2010-11-17 step). Again a re-record, not a new purchaser.

2011-12-30 — Reel NOT RETRIEVED

• Conveyance: Security interest / release (lienholder-to-borrower direction)
• Assignor: Silicon Valley Bank
• Assignee: JPI Commercial, LLC
• Correspondent: NOT RETRIEVED
• Context: SVB lien release back to Jazz's IP subsidiary. Securitization unwind.

2012-08-06 — Reel NOT RETRIEVED

• Conveyance: Security interest
• Assignor: EUSA Pharma (USA), Inc.; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals, Inc.
• Assignee: Barclays Bank PLC, as Collateral Agent
• Correspondent: NOT RETRIEVED
• Context: Group-wide securitization — collateral grant covering multiple Jazz/EUSA entities to Barclays as administrative/collateral agent. Financing, not ownership.

2015-07-09 — Reel NOT RETRIEVED

• Conveyance: Release by secured party
• Assignor: Barclays Bank PLC, as Collateral Agent
• Assignee: EUSA Pharma (USA), Inc.; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals, Inc.
• Correspondent: NOT RETRIEVED
• Context: Barclays lien release. Ends the secured-lender encumbrance line. Jazz Pharmaceuticals, Inc. (with JPI Commercial, LLC listed as co-assignee in the Google Patents current-assignee field) retains title.

Termination: patent expired 2019-12-22 (20 years from 1999-12-22 filing; no term extension apparent).

Timeline diagram

timeline
    title Ownership of US 6472431
    1999 : Filed by Orphan Medical Inc
    2000 : Inventors assign to Orphan Medical
         : Reincorporation in Delaware
    2002 : Patent issued Oct 29
         : Xyrem launched by Orphan
    2005 : Orphan acquired by Jazz
         : LB 1 Group takes security interest
    2008 : JPI Commercial grants security agreement
    2010 : Lien released by LB I Group
         : SVB security agreement recorded
         : Orphan Medical merged into Orphan Medical LLC
         : Title moved to JPI Commercial then Jazz
    2011 : First suit on 431 against Roxane
         : SVB lien released
    2012 : Barclays security interest recorded
    2015 : Barclays release recorded
    2019 : Patent expires Dec 22

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. Two names in this chain carry NPE-flavored suffixes and both check out as ordinary corporate finance structures, not licensing shells. JPI Commercial, LLC ("Commercial," not "IP/Licensing/Holdings") is a Jazz-controlled IP/financing subsidiary that appears only as a borrower/assignee-side party inside Jazz's own securitization and reorganization, and the chain terminates at Jazz Pharmaceuticals, Inc., an operating company with ~$1.6B in 2019 Xyrem revenue. Orphan Medical, LLC is the surviving conversion of the original patent-owning operating company. No registered-agent-only address, no single-purpose Delaware/Texas LLC, no evidence of zero-product status. Reel/frame confirmation of the JPI Commercial→Jazz step is still worth pulling, but the business substance is corroborated by SEC filings and merger agreements.

2. Known asserter in the chain — NOT PRESENT. No assignee or assignor at any point matches the public NPE directories (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities) or any Unified Patents / RPX high-frequency-plaintiff listing I can locate for this chain. Jazz Pharmaceuticals, Inc. is the plaintiff of record in every assertion involving this patent, which is the opposite of the NPE pattern.

3. Repeat correspondent across the chain — UNCLEAR / INSUFFICIENT DATA. I could not retrieve the correspondent of record for any entry in this chain, so I cannot test recurrence. This is the one place where the missing field genuinely matters: if a single outside firm signed every 2010–2012 recording (the reorg, the SVB lien, the Barclays lien), that would be unremarkable financing-counsel work; if successive recordals were signed by one repeat IP-specialist attorney across unrelated-looking LLCs, that would raise a question worth running. The record here shows no unrelated LLCs, so I would not expect a repeat-NPE-counsel hit — but the signal is not affirmatively cleared. Re-pull at https://assignmentcenter.uspto.gov/ before relying on the negative finding.

4. Cascading transfers — PRESENT (structurally), NON-NPE IN CONTEXT. There are five recordings compressed between 2010-11-12 and 2010-12-22 (two merger entries, two Orphan Medical LLC→JPI Commercial assignments, one JPI Commercial→Jazz assignment), plus duplicate re-recordings on 2010-11-26 and 2010-12-22. Under the checklist's <24-month, chained-LLC heuristic that pattern superficially scores. It does not survive scrutiny: the assignors and assignees are all members of one corporate family (Orphan Medical, Inc. → Orphan Medical, LLC → JPI Commercial, LLC → Jazz Pharmaceuticals, Inc.), the transfers coincide with the 2010-06-30 LB I → SVB refinancing, and the ultimate holder is the operating company. This reads as a lien-refresh-driven re-recording cycle plus an entity conversion, not an assertion-oriented chain. The duplicate 11-12 / 11-26 and 11-17 / 12-22 pairs are most likely corrective re-recordings.

5. Pre-litigation transfer — PRESENT but WEAK / benign. The final title movements to Jazz Pharmaceuticals, Inc. are dated 2010-11-17 and 2010-12-22; Jazz filed 2:11-cv-00660 (D.N.J.) asserting the '431 and '506 patents in early 2011 (consolidated into 2:10-cv-06108 on 2011-04-05). That places the transfer inside the 6-month window the checklist flags. However, the transferor and transferee are the same corporate group, the transferee had been the ultimate parent since 2005, and the patent had already been asserted by the group (Roxane I, No. 2:10-cv-06108, filed 2010-11-22, was filed before the Jazz-name recordings). The transfer therefore did not create standing that Jazz lacked or set venue — it cleaned up record title. Weak signal, explained.

6. Bankruptcy fire-sale — NOT PRESENT. No Chapter 7/11 proceeding appears for Orphan Medical or Jazz, and no sale of this patent in any proceeding. Jazz's 2009 "verge of bankruptcy" episode (alleged in the 2021 multi-district complaint) did not produce a patent sale — the chain shows only the SVB and Barclays lien lines, both later released. Orphan Medical's 2007 criminal plea is unrelated to insolvency.

7. Privateering — NOT PRESENT. Jazz retained and asserted the patent itself, in its own name, against competitor/generic ANDA filers (Roxane, Par, Amneal, Watson, Wockhardt, Teva, Hikma/Roxane, Lupin, Mallinckrodt). There is no transfer to a third-party NPE asserting on Jazz's behalf. The 2021 multi-district antitrust complaint (D. Minn. 0:21-cv-00737) alleges serial abuse of the patent system by the operating company, including alleged reverse-payment settlements with generics — that is a branded-pharma monopoly-maintenance theory, not the privateering pattern.

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN. It terminates at Jazz Pharmaceuticals, Inc. (with JPI Commercial, LLC listed as co-assignee of record). The patent was never neutralized — it was asserted for roughly a decade and expired 2019-12-22.

Verdict

Operating-company assertion.

Jazz Pharmaceuticals, Inc. — the manufacturer that has sold Xyrem (sodium oxybate) oral solution since the 2002 launch, with Xyrem revenue of roughly $1.6B in 2019 — holds record title, and every assertion of the '431 patent was brought in Jazz's own name against actual commercial competitors (first on the '431 in D.N.J. 2:11-cv-00660, consolidated into 2:10-cv-06108; subsequently through the 2:13-cv-07884, 2:14-cv-07757, 2:15-cv-05619/06548 and related ANDA actions; and defended in Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc., IPR2016-00370, which terminated by settlement per the PTAB order of 2016-05-17). The apparent cascade of 2010 recordings — Orphan Medical, Inc. → Orphan Medical, LLC → JPI Commercial, LLC → Jazz Pharmaceuticals, Inc., interleaved with the LB I Group and Silicon Valley Bank lien releases — is an internal reorganization plus secured-financing re-record, not a shell-LLC ladder: every party is in the same corporate family and the chain ends at the operating company. No known asserter, no bankruptcy sale, no defensive aggregator, and no third-party NPE appears anywhere in the chain.

Caveats to hold open: (a) reel/frame numbers were not retrieved, so the duplicate 2010-11-12/11-26 and 11-17/12-22 recordings are unresolved as to whether they are corrective re-records or separate conveyances; (b) correspondent of record was not retrieved, so signal 3 is not affirmatively cleared.

Verify at: https://assignmentcenter.uspto.gov/ — search patent number 6472431 (mirror: https://assignment.uspto.gov/patent/index.html).

I'll search for the specific patent's cited references from authoritative sources.

Let me retrieve the specific "Patent Citations" and "References Cited" data for this patent.

I found the face-of-patent U.S. references. Let me get details on each, plus foreign references and NPL.

I've hit my tool-call limit, so I'll compile the analysis from the authoritative sources already retrieved (the patent's own front page as reproduced in USPTO PTAB filings, downstream patents in the same family, and litigation records).

Prior-Art Analysis — US Patent 6,472,431

1. Number verification (literal, no auto-correction)

I searched specifically for 6472431. The retrieved record is:

• US 6,472,431 B2, "Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy"
• Application 09/470,570; filed Dec. 22, 1999; issued Oct. 29, 2002
• Priority: provisional 60/113,745 (Dec. 23, 1998)
• Assignee: Orphan Medical, Inc. (original); now Jazz Pharmaceuticals / JPI Commercial, LLC
• Source: https://patents.google.com/patent/US6472431/en

Because the application was filed Dec. 22, 1999, the pre-AIA 35 U.S.C. § 102 framework applies. Any printed publication or U.S. patent issued more than one year before Dec. 22, 1999 (i.e., before Dec. 22, 1998) is § 102(b) art. References issuing between the Dec. 23, 1998 priority date and the filing date are, at most, § 102(a)/(e) art.

Provenance note: The Google Patents "References Cited" block was not present in the fetched page text. I therefore reconstructed the face-of-patent citation list from the front page as OCR'd in USPTO PTAB petition exhibits and downstream family patents that carry the identical citation list — these sources independently agree. The primary sources are:

• PTAB petitions (front page reproduction): https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1459711](/patent/1459711)/ and .../1459762/
• Later family patent with identical list: US 11,147,782 (https://patentimages.storage.googleapis.com/e4/3a/bd/ef5023f3c9d78b/US11147782.pdf) and US 10,966,931
• Litigation exhibit (front page): https://insight.rpxcorp.com/litigation_documents/[9767926](/patent/9767926)

2. U.S. Patent Documents cited on the face of the '431 patent

The "U.S. Patent Documents" column of the '431 front page lists exactly nine references (reproduced identically across the sources above):

3. Foreign patent documents cited

Flag: A CourtListener reproduction of a '431-family front page also lists JP 57‑042651 (3/1982), JP 04‑049212 (2/1992), JP 05‑508422 (11/1993), and WO 2000038672. I could not confirm these belong to the '431 front page specifically (they may belong to a sibling/continuation). Treat the JP/WO entries as unverified for '431.

4. Non-patent literature cited (context for §102/§103)

The '431 front page carries a large "Other Publications" list, including: Arena (1980, J. Pharm. Sci. 69(3):356‑358); Bedard (1989); Berthier (1994); Broughton (1979); Snead (1981, Brain Res. 227(4):579‑589); Ferrara (1992, Br. J. Clin. Pharmacol. 34(3):231‑235); Gallimberti (1989; 1992); Gessa (1993); Grove‑White (1971); Laborit (1973); Ladinsky (1983); Lammers (1993, Sleep 16(3):216‑220); Lapierre (1988; 1990); Lee (1977); Lettieri & Fung (1978); Mamelak (1977, Biol. Psych. 12(2):273‑288); and others. These are printed publications and thus §102(b) art as to the methods of treatment recited in the specification, but none discloses the formulation concentration/pH limitations of issued Claims 1–7.

5. Ranked §102 anticipation assessment

Closest art — the reference that actually drove prosecution:

1. US 4,983,632 (Gessa et al.) — the leading §102 reference. It discloses a concentrated sodium‑GHB aqueous solution (~302 mg/mL, from 42.35 g/140 mL) that is preservative‑free. Under an inherency theory, such a concentrated GHB solution would inherently resist microbial growth, so it is the reference most capable of anticipating Claim 1 (and Claims 2, 4, 5). Prosecution turned on distinguishing it; the applicant argued Gessa does not teach using a GHB salt at ≥250 mg/mL as a microbial‑growth‑resistance agent. (This matches the previously generated section, which identified US 4,983,632 as the primary §102 reference — no contradiction.)

2. US 5,990,162 (Scharf) — §102(e) candidate for Claims 1 and 4 (soluble sodium oxybate at pH > 7; preservative‑free), but not §102(b) art.

3. US 4,393,236 (Klosa) — mentions aqueous GHB salt solutions and the sodium salt; §102 candidate for Claim 2, weak for Claim 1 absent concentration/pH disclosure.

4. US 5,840,331 (Van Cauter) and US 5,380,937 / 5,753,708 (Koehler) — cited and useful for §103 (and Claim 2 for the sodium‑salt point), but do not anticipate the issued rendering/concentration/pH claims.

5. US 4,374,441 (Carter), US 4,738,985 (Kluger), US 5,594,030 (Conte) — cited on the face, but I could not verify their disclosures; I will not assign them to specific claims without confirming their text.

Important caveat on all "anticipation" mappings above: issued Claim 1 is a "method of rendering an aqueous medium resistant to microbial growth" requiring the conjunctive steps of (a) adding a GHB salt, (b) reaching ≥ ~250 mg/mL, (c) adjusting pH to ~6–10, and (d) the resulting medium being chemically stable and resistant to microbial growth. True §102 anticipation requires each of these in a single reference, and most of these references disclose GHB solutions without expressly reciting the concentration‑plus‑pH‑plus‑resistance combination. In the actual litigation (the New Jersey actions and IPR2016‑00370), these references were pressed primarily as §103 combinations rather than clean §102 anticipations.

6. Additional prior art asserted in litigation (not necessarily on the '431 front page)

Beyond the face citations, the '431 invalidity contentions (reproduced in PTAB petition exhibits, e.g. petition 1459711) also assert: EP 0804 (Koehler — GHB salts as single/multi‑dose liquid solutions, sodium salt preferred, preservative‑free IV formulation), EP 236, CA 338 (4‑hydroxybutyric acid salt solutions pH 7.2–7.7 for injection), Vickers (GHB water‑soluble at all dilutions; marketed IV solution 2.42 g sodium 4‑hydroxybutyrate/10 mL, pH 8.2–8.9), Nema (buffers/pH‑adjusting agents, chelating agents, preservative limits), Mamelak 1977, and Remington's Pharmaceutical Sciences. Several of these (especially Vickers and CA 338) disclose the pH range and salt form of Claim 1 and are the substantive §102/§103 anchors for the concentration/pH limitations.

7. Explicit uncertainty flags

1. Three face citations are unverified as to disclosure — US 4,374,441 (Carter), US 4,738,985 (Kluger), US 5,594,030 (Conte). I did not retrieve their texts before reaching my search limit. Their titles/subject matter and any §102 mapping should be confirmed against the USPTO full‑text database.
2. The JP/WO foreign entries are unverified as belonging to the '431 front page (may belong to a sibling patent).
3. "What is claimed" — the issued Claim 1 text used above is corroborated by the PTAB petition exhibit reproducing it verbatim (https://patacts.uspto.gov/...petition 1459711), matching the previously generated section. No contradiction found, but I did not pull the issued claims directly from USPTO PatentCenter in this pass.
4. Date discrepancy in the task block — the instruction header states "Current Date: April 26, 2026" while the system date is 2026‑10‑01; this does not affect the prior‑art analysis, which depends only on pre‑1999 dates.

Sources cited: https://patents.google.com/patent/US6472431/en · https://ptacts.uspto.gov/ptacts/public-informations/petitions/1459711/ · https://ptacts.uspto.gov/ptacts/public-informations/petitions/1459762/ · https://insight.rpxcorp.com/patent/US5840331A · https://insight.rpxcorp.com/litigation_documents/9767926 · https://patentimages.storage.googleapis.com/e4/3a/bd/ef5023f3c9d78b/US11147782.pdf · https://patentimages.storage.googleapis.com/aa/b4/2c/688bf434ae8075/EP2931268B1.pdf · https://storage.courtlistener.com/recap/gov.uscourts.njd.[507190](/patent/507190)/gov.uscourts.njd.507190.1.0.pdf

I'll ground this obviousness analysis in actual prior-art references. Let me search for the key references cited in and around this patent family.

Strong leads. Let me pin down the specific prior-art references used against this patent — the Wockhardt IPR grounds (Gessa, CA 338, Vickers, EP '804) and the examiner's rejection.

Obviousness Analysis — US 6,472,431 under 35 U.S.C. § 103

Scope note / source caveat. The task instructs me to "use the results from the Prior Art section of this page." No such section was supplied in the materials provided to me (only the patent's own text, the bibliographic/summary sections, and the litigation summary). Rather than invent a "Prior Art section," I substituted the prior art of record for this patent, which I retrieved and which is directly on point: (i) the references the Examiner applied during prosecution of application 09/470,570; (ii) the references in the Wockhardt IPR petition against the '431 patent (IPR2016-00370, filed Dec. 22, 2015), whose exhibit list I recovered; and (iii) the invalidity contentions in the parallel Xyrem litigation. Where I could not verify a reference's precise teaching, I say so explicitly.

Contradiction flagged (vs. the previously generated litigation section). That section reported IPR2016-00370's petitioner as unidentified ("listed only as 'Unified Patents PTAB Data'"). The petition document itself shows the petitioner was Wockhardt (exhibits are labeled "WCK1001–WCK1007"), and the grounds are set out in a Wockhardt petition filed Dec. 22, 2015. This is a correction to the earlier section, not a new case.

1. The claims at issue

All seven claims are method claims directed to rendering an aqueous medium resistant to microbial growth (consistent with the previously generated claim overview):

• Claim 1: adding a GHB salt to an aqueous medium; adjusting concentration to ≥ about 250 mg/ml; adjusting pH to about 6 to about 10; "so that the medium is chemically stable and resistant to microbial growth."
• Claim 2: salt is sodium GHB.
• Claim 3: about 310–750 mg/ml; pH about 6–9.
• Claim 4: medium contains no preservative.
• Claim 5: about 250–750 mg/ml.
• Claim 6: pH-adjusting agent is an organic acid.
• Claim 7: acid selected from malic, citric, acetic, boric, lactic, hydrochloric, phosphoric, sulfuric, sulfonic, nitric.

The critical structural feature for § 103 is that claim 1 recites no chemical structure, no new salt, and no new excipient — it recites adjusting two well-known formulation variables (concentration and pH) of a known drug solution to arrive at a result ("chemically stable and resistant to microbial growth"). That framing drives the whole analysis. As the Wockhardt petition put it, applicants during prosecution admitted the claims were directed to "a new use of an 'old compound,' a [GHB] acid salt," and under Atlas Powder Co. v. Ireco Inc., 190 F.3d 1342, 1347 (Fed. Cir. 1999), "the discovery of a previously unappreciated property of a prior art composition… does not render the old composition patentably new."

2. Level of ordinary skill (POSA)

Per the Wockhardt petition and the declaration of Dr. Ralph Tarantino, a POSA would have had a Ph.D. in pharmaceutics, microbiology, chemistry, or a related discipline with ≥2 years' experience formulating pharmaceutical solutions (or an M.S./B.S. with 4–6 years' experience), typically working in a multidisciplinary team including a microbiologist and a formulation scientist. This is uncontroversial and the patent does not appear to dispute it.

3. Scope and content of the prior art

3.1 Gessa et al., US 4,983,632 ("Gessa '632")

Filed June 2, 1989; issued Jan. 8, 1991. Discloses:

• Pharmaceutical compositions containing GHB salts (sodium, potassium, calcium, magnesium) and pharmaceutically acceptable excipients, for oral or parenteral administration (see https://patents.google.com/patent/US4983632).
• GHB salt content 12.5%–50% by weight — i.e., a range spanning roughly 125–500+ mg/ml in aqueous solution.
• Example 2: 6.05 g of "gamma-hydroxybutyric acid, sodium salt" in 20 mL = 302.5 mg/mL — a concentration above the claimed "at least about 250 mg/ml."
• An injectable aqueous formulation of sodium GHB free of preservatives.

3.2 CA 338 (ES 302338, Chem. Abstr. Vol. 65 (1966), CAN 65:81550)

"Solutions of 4-hydroxybutyric acid salts for injection." Discloses preparation of 4-hydroxybutyric acid salt solutions — including sodium 4-hydroxybutyrate — of pH 7.2–7.7 for injection, prepared by sequential addition of γ-butyrolactone, water, and sodium hydroxide. pH 7.2–7.7 sits squarely inside claimed "about 6 to about 10."

3.3 Vickers, M.D., "Gammahydroxybutyric Acid," Newer Intravenous Anesthetics, Int'l Anesthesiology Clinics 7(1):75–89 (1969) ("Vickers")

Discloses GHB as an intravenous anesthetic agent and its clinical use as a concentrated parenteral solution. (See also the '431 specification's own citation of "Vickers, 1969" for GHB's rapid onset/short effect.) Caveat: I could not retrieve Vickers' verbatim concentration/pH statements; see § 7.

3.4 EP '804 (Tessitore et al., EP 0 616 804 A1, published Sept. 28, 1994)

Discloses administration of GHB salts (sodium particularly preferred) as single- or multi-dose liquid solutions, including an intravenous formulation free of preservative, with pH adjusted for administration (see the EP '804 discussion in the parallel Xyrem invalidity contentions).

3.5 Van Cauter et al., US 5,840,331 ("Van Cauter '331")

Discloses use of γ-hydroxybutyrate to stimulate sleep-related GH/prolactin secretion, and expressly states that the compositions "may be administered in the form of injectable compositions either as liquid solutions or suspensions" and that "the pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to well known parameters" (col. 7). This is a textbook "routine optimization" teaching (see https://patents.google.com/patent/US5840331).

3.6 Scharf, US 5,990,162 and Scharf 1985, J. Clin. Psychiatry 46(6):222–225

Teaches GHB is effective in treating narcolepsy/sleep disorders and teaches the twice-nightly dosing regimen (3 g at bedtime; 3 g 2–5 h later). Relevant primarily to the treatment claims that lived in the 09/470,570 application family.

3.7 Admitted prior art (the '431 specification itself)

The specification concedes the problem and much of the solution:

• "GHB degrades into gamma-butyrolactone (GBL) … depending upon the pH and other factors";
• "the contamination by microorganisms in GHB solutions rapidly surpass[es] acceptable limits";
• "preservatives can adversely affect the pH and thus, GHB's stability";
• "there is an immediate need for effective solutions of GHB that are stable to biological or chemical degradation."

This is an admission of the motivation and the problem, and it frames the alleged invention as a solution to a known formulation problem.

3.8 Secondary art

• US 4,393,236 — calcium/magnesium 4-hydroxybutyrate salts dispensable as aqueous solutions; sodium salt induces sleep; analgesic utility.
• Nema et al. (1997), PDA J. Pharm. Sci. Technol. — injectable excipients; preservatives may be disallowed depending on route; and a table of buffers/pH-adjusting agents including organic and inorganic acids.
• "Malic Acid," Handbook of Pharmaceutical Excipients (2d ed. 1994) — malic acid as a conventional, metabolizable acidulant.
• Admitted prior art at p.12, lines 3–8 of the specification, applied by the Examiner.

4. Combination A — Gessa '632 + CA 338 (claims 1–5)

Motivation to combine. Both references concern the same drug in the same dosage form (an aqueous GHB salt solution for human administration). A POSA formulating a GHB solution would: (a) select Gessa's demonstrated 302.5 mg/mL sodium-GHB solution (Example 2) as the starting formulation; and (b) set pH to the physiologically compatible, injection-tolerated value taught by CA 338 (7.2–7.7) rather than leaving pH uncontrolled. That is optimization of two known, result-effective variables by conventional means (cf. In re Aller, 220 F.2d 454; In re Antonie, 559 F.2d 618). The KSR rationales apply directly: the problem (chemical stability + microbial contamination of GHB solutions) was known and expressly acknowledged in the specification; the available solutions were "a finite number of identified, predictable solutions" (raise concentration; adjust pH; add preservative); and the results were predictable—KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 416–21 (2007).

Claims 2–5 fall with claim 1: claim 2 (sodium salt) is Gessa's expressly preferred salt; claim 3's "about 310 mg/ml" is one rounding step from Gessa's 302.5 mg/mL and lies inside Gessa's 12.5–50% w/w range; claim 4 (no preservative) is taught by Gessa's preservative-free injectable and EP '804; claim 5 (250–750 mg/ml) is routine optimization within the known solubility envelope (the '431 specification itself concedes >150 mg/ml solutions are "suitably resistant," undermining any assertion that the recitation of an upper bound is inventive).

5. Combination B — Gessa '632 + CA 338 + EP '804 (claims 6–7)

Claims 6–7 require the pH-adjusting agent to be an organic acid (claim 6) chosen from a nine-member list (claim 7). The reliance on EP '804 for this limitation indicates the petitioner used EP '804 to supply the acid pH-adjusting/acidulant teaching for a preservative-free multi-dose GHB solution. Independently, the organic-acid limitation is amply supplied by:

• Van Cauter '331 ("pH … adjusted according to well known parameters");
• Nema (1997) (buffers/pH adjusters incl. organic and inorganic acids);
• "Malic Acid," Handbook of Pharmaceutical Excipients and the parallel '083 patent teaching of malic/acetic/lactic acid as metabolizable acidulants.

Selecting an organic acid (malic acid in particular) from the small, known set of pharmaceutically acceptable, metabolizable acidulants is the paradigm of obviousness: the members are structurally and functionally related, and the prior art supplies the motivation (tolerability, taste, metabolic clearance). Caveat: I could not retrieve the specific EP '804 passage the petitioner mapped to claims 6–7; see § 8.

6. Combination C — Vickers alone (claims 1–5); Vickers + EP '804 (claims 6–7)

The Wockhardt petition asserts Ground 3: claims 1–5 obvious over Vickers alone, and Ground 4: claims 6–7 obvious over Vickers and EP '804. The theory is that Vickers, a 1969 clinical-anesthesia reference on GHB, itself discloses a concentrated, pH-controlled aqueous sodium-GHB solution adequate to meet claim 1, so that the ordinary-skill formulator need not even combine references. I flag that I could not retrieve the full Ground 3 element-by-element mapping or Vickers' precise concentration figure (see § 8); however, the legal structure of Ground 3 is that Vickers is an anticipating-scope reference for a single-reference obviousness/anticipation attack, and Ground 4 adds EP '804 only for the acid pH-adjuster of claims 6–7.

7. Combination D — the Examiner's own prosecution ground (claims 1–6, 11–15, 17, 27, 62–69)

During prosecution of 09/470,570 the Examiner rejected the claims under § 103(a) over Gessa (US 4,983,632) and Van Cauter (US 5,840,331) in view of admitted prior art (spec. p.12, lines 3–8) and Scharf (US 5,990,162). The Examiner reasoned that:

"the determination of pH of claimed composition, the determination of dosage form having optimum therapeutic index, or the use of pH adjusting agents such as acids, bases and buffering agents … is well considered within the level of one having ordinary skill in the art, and the artisan would be motivated to formulate a pharmaceutical composition having optimum therapeutic index … the use of preservatives … [is] old and well known in the art."

That is the classic KSR/routine-optimization rationale. Applicants' rebuttal was, in substance: (i) the references give no motivation to raise GHB concentration to render the solution antimicrobial; and (ii) "one would simply add the preservatives disclosed by the references … and hope for the best." That argument is vulnerable under KSR: the existence of one known route (add a preservative) does not render another predictable route (concentrate the solution and set pH) nonobvious, especially where the specification itself admits preservatives degrade GHB and raise pH-stability problems, supplying an affirmative reason to avoid them.

8. Why a POSA would have combined the references (motivation, consolidated)

1. Common field, common problem, common dosage form. Every reference is a GHB pharmaceutical formulation reference; the claimed "rendering" is merely a stated result of formulating a GHB solution at defined concentration/pH.
2. Express "routine parameters" teaching. Van Cauter '331 states pH and concentration "are adjusted according to well known parameters" — the single strongest motivation-to-combine statement in the record.
3. Known problem + finite predictable solutions. The specification admits GHB solutions degrade to GBL and are microbially contaminated; KSR teaches that where a known problem has a finite number of identified, predictable solutions, following one of them is obvious. Here the identified options were: increase concentration, adjust pH, or add preservative.
4. Design incentive to concentrate and to avoid preservative. The specification itself notes the need for a concentrated product (volume/cost/handling) and that preservatives destabilize GHB — so a POSA had an affirmative reason to move to higher-concentration, preservative-free, pH-adjusted solutions (as taught by Gessa's and EP '804's preservative-free injectables).
5. Physiological pH as a default target. CA 338's pH 7.2–7.7 and general physiological pH (~7.4) provide the anchor value within claimed 6–10.
6. Inherency. "Chemically stable and resistant to microbial growth," recited as a result, are inherent properties of the resulting solution composition; unappreciated properties do not confer patentability (Atlas Powder, 190 F.3d at 1347).

9. Rebuttal considerations (what could defeat the prima facie case)

• Unpredictability / unexpected results. The patent's FIG. 1 and Table 2 show a non-linear, two-variable relationship: 150 mg/ml fails at every pH (3–9); ≤150 mg/ml is "poorly resistant"; ≥250 mg/ml is resistant across ~pH 5–7.5; and resistance decreases above ~750 mg/ml at pH >7.5. The patentee can argue that the concentration × pH interaction was unpredictable and that the art gave no reason to expect self-preservation by GHB per se. This is the patentee's strongest § 103 position and the one the Examiner initially found persuasive for the allowed method claims.
• "Teaching away" / different approach. Applicant's prosecution argument that a POSA "would simply add a preservative" is a different-approach argument; under KSR it generally fails, but it retains some force if the record shows a strong bias toward preservatives.
• Secondary considerations. The enormous commercial success of Xyrem®/sodium oxybate is a potential objective-indicia argument, but nexus is the weak point: the product's success is plausibly attributable to clinical efficacy, orphan exclusivity (ODE), the REMS distribution patents, and the convenience of a concentrated liquid — not necessarily to the claimed ≥250 mg/ml/pH 6–10 self-preservation step. Note also that the Wockhardt/Par position is that any commercial success flows from the old compound (sodium GHB), not the formulation step.
• § 112 overlay (not § 103, but relevant to the claim-scope question). The earlier sections flagged a drafting mismatch (claims 6–7 reference "said pH-adjusting agent," absent from claim 1) and improper multiple-dependent claims 4 and 7. If claims 4/7 are invalid as to form, the effective § 103 attack is narrowed to claims 1–3, 5–6.

10. Claim-by-claim § 103 conclusion

Overall: claims 2–7 are very likely obvious over the art of record; claim 1 is likely obvious but its disposition turns on whether the patentee can substantiate unexpected results for the concentration×pH self-preservation relationship given the FIG. 1/Table 2 data. The one-criterion general rule — that merely discovering an inherent property of a known composition is not patentable — cuts strongly against claim 1.

11. Stated uncertainties and gaps

1. No "Prior Art section" was supplied in the prompt; the prior-art identification here comes from the '431 prosecution file, the Wockhardt IPR2016-00370 petition, and the parallel litigation contentions. If a specific prior-art list was intended, please supply it and I will re-run the mapping.
2. Vickers (1969): I could not retrieve its verbatim concentration/pH teachings or the Ground 3 element chart. Ground 3 is reported as asserted (title/caption), not verified in detail.
3. EP '804: I could not verify the specific passage mapped to the organic-acid limitation of claims 6–7.
4. IPR outcome: IPR2016-00370 terminated by settlement; there is no final PTAB or Federal Circuit merits ruling on the '431 claims, so no authoritative adjudication of the § 103 questions above exists. The Examiner's § 103 rejections were withdrawn after applicant's argument — i.e., the obviousness question was resolved at the PTO level by argument, not by evidence-heavy trial.
5. Markman: The D.N.J. construction of "resistant to microbial growth" (Jazz v. Roxane, Sept. 14, 2012) bears directly on claim scope and thus on inherency, but I did not retrieve the verbatim construction.
6. Unconfirmed docket defendants (2:15-cv-05619; 2:15-cv-06548; 2:17-cv-05487; 2:17-cv-04439) remain unconfirmed; the Wockhardt IPR implies Wockhardt was an ANDA filer and a '431 challenger, corroborating (but not proving) the earlier guess that Wockhardt and/or Lupin appear in the 2015 NJ actions.